Synthetic Peptide APIs Portfolio

Synthetic Peptide APIs Portfolio
Product Description

US DMF Approved:

  • Vasopressin 
  • Icatibant acetate 
  • Leuprolide acetate 
  • Linaclotide 
  • Etelcalcetide 
  • Desmopressin 
US DMF Filed:
  • Calcitonin salmon 
  • Ganirelix acetate 
  • Degarelix
  • Glatiramer acetate 
  • Plecanatide 
  • Teriparatide 
  • Octreotide acetate 
  • Liraglutide 
Validation complete:
  • Semaglutide

Read more Show less

CuraTeQ Biologics

  • IN
  • 2024
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
Biopharmaceutical
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Bone & Joint Health; Digestive Health; International Approvals/Standards; Price; Product Features; Prompt Delivery; Quality Service; Reputation; Weight Loss Management
More specifications Fewer specifications
Sales Markets
Show more Show less

CuraTeQ Biologics

  • IN
  • 2024
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
Biopharmaceutical
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile

More Products from CuraTeQ Biologics (1)

  • Biosimilars Portfolio

    Product Biosimilars Portfolio

    • Pegfilgrastim (Filed with EMA) • Filgrastim (Filed with EMA) • Trastuzumab (Filed with EMA, MHRA, Received recommendation for marketing authorization in India) • Bevacizumab (Filed with MHRA) • Omalizumab (Global PhIII ongoing) • Denosumab (Global PhIII ongoing) • Ranibizumab (Global PhIII ongoing...

CuraTeQ Biologics resources (1)

  • Biosimilars Pipeline

    Brochure Biosimilars Pipeline

    CuraTeQ Biologics is a biopharmaceutical company based in Hyderabad, India. We have a pipeline of 14 biosimilars of which: 3 products are filed with EMA, one product is filed with MHRA, and 4 products are in global Ph3 clinical trials. Dazublys™, our Trastuzumab biosimilar has received marketing authorization approval in India, and is also filed with EMA.